Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Waguespack SG, et al. Among authors: leyvraz s. Eur J Endocrinol. 2022 Apr 29;186(6):631-643. doi: 10.1530/EJE-21-1259. Eur J Endocrinol. 2022. PMID: 35333737 Free PMC article.
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, Pappo A, López-Ríos F, Reeves JA, Fellous M, Penault-Llorca F, Rudzinski ER, Tabatabai G, Vassal G, Drilon A, Trent J. Yang JCH, et al. Among authors: leyvraz s. BMC Cancer. 2022 Jun 7;22(1):625. doi: 10.1186/s12885-022-09687-x. BMC Cancer. 2022. PMID: 35672677 Free PMC article.
Challenges in the Diagnosis of NTRK Fusion-Positive Cancers.
Gautschi O, Bubendorf L, Leyvraz S, Menon R, Diebold J. Gautschi O, et al. Among authors: leyvraz s. J Thorac Oncol. 2020 Jul;15(7):e108-e110. doi: 10.1016/j.jtho.2019.05.001. J Thorac Oncol. 2020. PMID: 32593446 Free article. No abstract available.
Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center.
Joss RA, Bürki K, Dalquen P, Schatzmann E, Leyvraz S, Cavalli F, Ludwig C, Siegenthaler P, Alberto P, Stahel R, et al. Joss RA, et al. Among authors: leyvraz s. Cancer. 1990 Jun 1;65(11):2426-34. doi: 10.1002/1097-0142(19900601)65:11<2426::aid-cncr2820651104>3.0.co;2-3. Cancer. 1990. PMID: 2159837 Clinical Trial.
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
Borner MM, Castiglione M, Bacchi M, Weber W, Herrmann R, Fey MF, Pagani O, Leyvraz S, Morant R, Pestalozzi B, Hanselmann S, Goldhirsch A. Borner MM, et al. Among authors: leyvraz s. Ann Oncol. 1998 May;9(5):535-41. doi: 10.1023/a:1008270916325. Ann Oncol. 1998. PMID: 9653495 Free article. Clinical Trial.
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G; Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. Leyvraz S, et al. J Natl Cancer Inst. 2008 Apr 16;100(8):533-41. doi: 10.1093/jnci/djn088. Epub 2008 Apr 8. J Natl Cancer Inst. 2008. PMID: 18398095 Clinical Trial.
216 results